The most common adverse events associated with bromocriptine mesylate
are nausea, fatigue, dizziness, vomiting and headache. Clinical trial
data reveal that bromocriptine mesylate at doses up to 4.8 mg per day
was not associated with a different rate of all-cause adverse events
compared with placebo. However, the drug is known to be associated with
nasal stuffiness, nausea, headache, constrictive pericarditis,
neuroleptic malignant syndrome, and hypotension. The incidence of
hypoglycemia was 6.9% among bromocriptine mesylate-treated patients
compared with 5.3% of patients receiving placebo. In the pooled CYCLOSET
phase 3 clinical trials (CYCLOSET N = 2298; placebo N = 1266) data,
adverse events leading to discontinuation occurred in 539 (24%)
CYCLOSET-treated patients and 118 (9%) placebo-treated patients. Pramlintide powder
This between-group difference was driven mostly by gastrointestinal
adverse events, particularly nausea. This drug is contraindicated in
patients with known hypersensitivity to bromocriptine or ergot-related
drugs. It is also contraindicated in patients with syncopal migraine.
Bromocriptine increases the likelihood of a hypotensive episode among
patients with syncopal migraine. It is also contraindicated in nursing
women as it may inhibit lactation.
There are post-marketing reports of stroke in these patients although
causality has not been proven. • PRAMLINTIDE The hormone amylin ( Figure
12 ) is co-secreted with insulin by the pancreatic β cells in response
to nutrient stimuli [268;269]. Patients with type 1 diabetes may develop
an absolute deficiency of both insulin and amylin [270], and those with
type 2 diabetes have impaired beta-cell secretion amylin in response to
a meal. Amylin suppresses post-prandial arginine-stimulated glucagon
secretion [272] and slows gastric emptying time [273]. Pramlintide® is a
soluble synthetic analog of human amylin, allowing clinical application
of this ...
